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Abstract
Purpose The aim of the study is to characterize changes in
circulating proteasome (c-proteasome) activity following mild
traumatic brain injury in children.
Methods Fifty children managed at the Department of Pedi-
atric Surgery because of concussion—mild head injury was
randomly included into the study. The children were aged
11 months to 17 years (median=10.07+−1.91 years). Plasma
proteasome activity was assessed using Suc-Leu-Leu-Val-
Tyr-AMC peptide substrate, 2–6 h, 12–16 h, and 2 days after
injury. Twenty healthy children admitted for planned inguinal
hernia repair served as controls.
Results Statistically significant elevation of plasma c-
proteasome activity was noted in children with mild head
injury 2–6 h, 12–16 h, and 2 days after the injury.
Conclusions Authors observed a statistically significant up-
ward trend in the c-proteasome activity between 2–6 and 12–
16 h after the mild head injury, consistent with the onset of the
symptoms of cerebral concussion and a downward trend in the
c-proteasome activity in the plasma of children with mild head
injury between 12–16 h and on the second day after the injury,
consistent with the resolving of the symptoms of cerebral
concussion. Further studies are needed to demonstrate that
the proteasome activity could be a prognostic factor, which
can help in further diagnostic and therapeutic decisions in
patients with head injury.
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Introduction
Head trauma occurs commonly in children. Most children
with head trauma are young, male, and have a mild injury
[31]. Mild head injury is generally associated with symptoms
such as a brief loss of consciousness, disorientation, or
vomiting. Patients with mild head injury usually have GCS
scores of 13 to 15, measured approximately 30 min after the
injury [30, 31]. The onset of impairment is rapid, but usually
short-lived, and generally resolves spontaneously. Still, head
injury is the most common cause of death and disability
during childhood [19, 30, 31].
Consequently, children after mild head injuries are com-
monly admitted to emergency or surgical departments,
overdiagnosed, and hospitalized. This large group of patients
produces significant costs to the public health system. There-
fore, new biochemical markers of mild head injuries are
needed.
Ubiquitin-proteasome system is the principal enzyme sys-
tem responsible for protein degradation, which has been re-
ported to be abundantly expressed in the various cell types of
the central nervous system [9, 28]. The addition of
polyubiquitin chains to a protein results in its translocation
to the proteasome, a large multi-subunit protease, which then
results in its degradation. Proteasome catalytic function not
only degrades most cytosolic proteins, but plays an essential
role in numerous cellular processes including cell cycle pro-
gramming, transcriptional control, signal transduction, and the
elimination of damaged proteins [37]. The clearance of dam-
aged proteins is indispensable in order to provide the neces-
sary conditions for cellular repair and plasticity. Induction of
proteasome has been reported after different traumatic
stressors, such as hyperoxia, radiation, or oxidative damage
[1, 32]. It is known that the oxidized proteins are tagged for
degradation, and that activity of proteasome complex can be
induced by oxidative protein damage in cell culture [32].
Recent in vitro study reports have demonstrated ubiquitin-
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proteasome enzyme system playing an essential role in rapid
phase of ischemic preconditioning of cultured neurons [21,
22]. Also, ubiquitin-proteasome system activation is one of
the important mechanisms regulating the cell death pathways
in ischemic neurons [33]. Study by Szabo et al showed that
experimental brain trauma elevates the levels of protein oxi-
dation in the injured cerebral cortex. Correlation analysis
showed that protein oxidation was positively associated with
proteasome activity [32].
Moreover, patients with head injury exhibit negative nitro-
gen balance, enhanced rates of whole body protein break-
down, and a sustained rise in urinary 3-methylhistidine excre-
tion, an index of muscle myofibrillar protein breakdown [18].
Overexpression of multiple components of the ubiquitin-
proteasome proteolytic pathway in muscle biopsies from head
trauma patients strongly suggests that this pathway is involved
in the breakdown of contractile protein in humans [18].
The purpose of this novel human study was to characterize
changes following mild head injury in children in the circu-
lating 20S proteasome activity.
Methods and materials
Patients
The study was approved by the local Ethics Committee as an
audit of a clinically agreed-upon protocol of investigation and
treatment. All parents of the patients gave informed consent
for both clinical and biochemical follow-up. The study popu-
lation comprised 50 children admitted due to mild head injury
to Department of Pediatric Surgery of Medical University of
Bialystok, between 2010 and February 2014. Patients were
randomly included in the study. Patients were aged 11 months
to 17 years (median=10.07+−1.91 years). There were 19 girls
and 31 boys. Falls were the most common mechanism of
injury for our patients sustaining mild head injury, followed
by motor vehicle crashes, pedestrian and bicycle accidents,
and sports-related trauma. The diagnosis of mild head injury
was based upon the following symptoms: loss of conscious-
ness, amnesia, vomiting, severe headache, GCS score 13–15,
and normal head CT. Patients with mild head injury were
managed according to the conventional lines of head injury
treatment in our department.
Exclusion criteria were GCS score below 13, abnormal
head CT, hospital admission later than 6 h after injury, severe
preexisting infections, and other diseases that required long-
term medication.
Twenty healthy children aged 1–14 years (median=4.36+
−2.03 years), admitted to the Department of Pediatric Surgery
for planned inguinal hernia repairs between 2010 and
2012 (6 girls, 14 boys), served as controls. Exclusion
criteria were hospital admission later than 6 h after injury,
severe preexisting infections, and diseases that required long-
term medication.
Methods
Venous blood samples (1–2 ml) were drawn after admission,
2–6, and 12–16 h after the injury and in the morning of the
subsequent 2 days along with the routine laboratory work-up.
Blood samples were collected in plasma test tubes (EDTA
tubes), plasma prepared according to the standard hospital
procedures and stored at −80 °C until further analysis. After
all blood samples were collected and patient data recorded,
circulating 20S proteasome activity in the plasma was deter-
mined with the investigators blinded to the patient-related data.
The thawed plasma samples were centrifuged to remove
fibrinogen, and then, each sample was diluted to the protein
concentration of 5.0mg/mLwith 100mmol/LTris-HCl (pH 7.5)
supplemented with inhibitors of other proteases: ethylene di-
amine tetraacetic acid (EDTA, 1 mmol/L), trans-epoxysuccinyl-
leucylamide (4-guanidino)butane (E-64, 10 μmol/L), and
pepstatin (1 μmol/L) (Sigma, USA). Total protein concentration
in plasma samples was determined using the Bio-Rad assay
reagent with bovine serum albumin as the standard.
The proteasome activity in the plasma was measured using
the assay designed to measure chymotrypsin-like protease
activity (ChT-L) of proteasomes using the fluorogenic peptide
substrate the Suc-Leu-Leu-Val-Tyr-AMC in the presence of
sodium dodecyl sulfate (SDS) as an artificial proteasome
activator. The reaction mixture (total volume, 30 μL)
contained 100 mmol/L Tris-HCl buffer (1 mmol/L EDTA,
EGTA, 0.05 % SDS, pH 7.5), and 10 μL 0,5 mmol/L Suc-
Leu-Leu-Val-Tyr-AMC substrate. Ten microliters of nonacti-
vated plasma sample or 10 μL of plasma sample activated for
15 min at room temperature with 10 % SDS added to the
reaction mixture. To confirm the specificity of the assay, the
plasma was preincubated with the selective proteasome inhib-
itor epoxomicin (1.0 μmol/L) for 15 min before the addition
of a substrate. The samples were incubated at 37 °C for 30–
60 min, since during this time, a linear relation between time
and product generation was obtained. After incubation, the
reaction was stopped by the addition of 1 mL of 100 mmol/L
monochloroacetate—30mmol/L sodium acetate, and the sam-
ples were centrifuged to remove any insoluble material. Fluo-
rescence of the released AMC was determined at 380 nm
excitation and 460 nm emission wavelength in a Hitachi
F-2000 fluorimeter. The 20S proteasome ChT-L activity was
calculated from the differences between the fluorescence in
the sample incubated with the substrate and the sample incu-
bated with 0.1 % dimethyl sulfoxide (DMSO). One unit of the
20S proteasome ChT-L activity was expressed as the amount
of AMC released from the substrate per minute (pmol/min).
All assays were performed in triplicates.
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For identification of 20S proteasome antigen, a plasma
sample (20 μg of total protein per line) was electrophoresed
by SDS-polyacrylamide gel electrophoresis (PAGE) in a 10%
separation gel under reducing conditions, and then proteins
were electroblotted onto nitrocellulose membranes. The nitro-
celluloses were incubated for 1 h with the monoclonal anti-
body reacting with the human β5 subunit (C2) of the 20S
proteasome (Affiniti Research Products Ltd., UK). The im-
munoreactive proteins were visualized with an alkaline
phosphate-conjugated anti-rabbit IgG as the secondary anti-
body and p-nitrophenyl phosphate as the phosphatase sub-
strate (Sigma, USA).
Statistics
Proteasome activity is described as median with 25th and 75th
percentiles. All data are presented along with the exact num-
ber of measurements. Because the proteasome activity in the
plasma of our patients did not pass the normality test, the
Mann-WhitneyU test and the Kruskal-WallisH test were used
to compare differences between groups. Statistical analyses
were calculated with the STATISTICA PL release 10.0 Pro-
gram. A two-tailed p<0.05 was considered significant.
Results
The circulating proteasome (c-proteasome) activity was de-
tectable in all plasma specimens from patients and controls.
In the group of our patients with mild head injury, the c-
proteasome activity 2–6 h after the injury, 12–16 h after injury,
and 2 days after injury were above the range of activity
measured in controls which was statistically significant
(Fig. 1). There was an upward trend in the c-proteasome
activity between 2–6 and 12–16 h after the injury, consistent
with the onset of the symptoms of cerebral concussion and a
downward trend in the c-proteasome activity in the plasma of
children with mild TBI between 12–16 h and on the second
day after the injury, consistent with the resolving of the
symptoms of cerebral concussion. The c-proteasome activity
was not associated with age or sex (p>0.05, data not shown).
Discussion
Mild head injury usually occurs due to contact or acceleration-
deceleration forces. The goal of the evaluation of children
with head trauma is to identify those who may require imme-
diate intervention or close follow-up. Although associated
intracranial injury occurs in a small percentage of those chil-
dren who have a normal neurologic examination at presenta-
tion, it must be recognized in order to prevent deterioration
and subsequent morbidity or mortality [19, 30, 31].
Mild head injury causes a reduction in cognitive capacity
[27, 29], possibly due to deterioration in the molecular sub-
strates that support synaptic plasticity and function. Most forms
of synaptic plasticity involve protein synthesis and limited
protein degradation [11], which are under the spectrum of the
action of proteasome complex. The proteasome system is re-
sponsible for the degradation of altered cellular proteins, in-
cluding those modified by reactive oxygen species. Oxidized
proteins are tagged for degradation either by the change of
hydrophobicity or by ubiquitination, such that residual amino
acids can be recycled for protein synthesis [6]. In our study, we
wanted to check the hypothesis that c-proteasome activity in the
plasma of children withminor head injury is associated with the
onset and resolving of symptoms of cerebral concussion.
Several lines of evidence strongly suggest the ubiquitin-
proteasome cascade is involved in responses to CNS stress or
injury. Weih et al demonstrated that proteasome activation is
needed for the proteolysis of oxidized proteins in cortical
neurons under glucose and oxygen deprivation [34]. Another
study showed that enhancement of proteasome activity poten-
tially reduces neuronal vulnerability to oxidative injury [35]. A
transgenic mouse study indicated that loss of an individual
proteasome subunit—LMP2—alters mice brain function [20].
Using antibodies that recognize the entire 20S proteasome
complex, Mengual et al [23] found that the proteasome is
ubiquitously, although not homogeneously, expressed in rat
CNS, and that subcellular distribution is localized to cytoplas-
mic, nuclear, dendritic, and axonal processes, and in synaptic
boutons. Also in the group of our patients with mild head
injury, the c-proteasome activity 2–6 h after the injury, 12–
16 h after injury, and 2 days after injury were above the range of
activity measured in controls which was statistically significant.
Earlier findings suggested that systemic 20S proteasome
concentrations reflect cellular damage independent of the
underlying cause of the disease and circulating proteasomes
might be a useful biomarker to assess disease severity or
progression [6, 10, 17]. In our study, we used assay of plasma
20S proteasome ChT-L activity for the measurement of circu-
lating proteasomes. Several authors confirmed the specificity
of this assay with highly selective proteasome inhibitors [25].
The most common method of detecting circulating
proteasomes in plasma or serum is the enzyme-linked
immunoabsorbent assay (ELISA) test employing antibodies
directed against the constitutive α6 (C2) subunits of the 20S
proteasome [2, 5]. ELISA-based assay does not provide
information about circulating proteasome activity in the
plasma, since only intact 20S proteasome complexes, but
not subunit fragments, are enzymatically active. The
method allows for the detection of only the intact 20S
proteasome complexes, since free catalytic subunits are
enzymatically inactive, so 20S proteasome ChT-L activ-
ity assay in plasma is a good alternative to ELISA for
the measurement of circulating proteasomes [2, 5].
Childs Nerv Syst (2014) 30:1191–1196 1193
A decline in proteasome function is believed to underline
many neurodegenerative diseases [12], where impaired func-
tion of the proteasomes has been proposed to contribute to the
pathogenesis of degenerative diseases because of an accumu-
lation of abnormal proteins [2, 7, 13, 14]. Impairment in the
ubiquitin-proteasomal system also has been suggested as one
of the underlyingmechanisms of Parkinson’s and Alzheimer’s
disease [3, 15]. Study of Alzheimer disease autopsy brain
samples suggested that 19S and 20S proteasome subunits
are localized in neurons [15].
In contrast to its role as pathogenic factor in neuro-
degenerative diseases, limitation of protein turnover af-
ter cellular damage would rather support regenerative
processes. Increasing evidence indicates that reversible
proteasome inhibitors can be therapeutic agents even
neuroprotective during ischemic brain injury [36, 38].
Reduction of proteasome function is seen as key for
reducing CNS damage from acute traumatic brain injury
and stroke. Several studies have demonstrated that sup-
pression of function by proteasome inhibitor administra-
tion leads to better outcome from CNS injury [8, 35,
38]. In our experiments, we observed an upward trend
in the c-proteasome activity between 2–6 and 12–16 h
after the injury, consistent with the onset of symptoms
of cerebral concussion and a downward trend in the c-
proteasome activity in the plasma of children with mild
head injury between 12–16 h and 2 days after the
injury, consistent with the resolving of the symptoms
of cerebral concussion.
Another group of proteasome family—immunoproteasomes
have been detected in human brains and indicate that
immunoproteasomes participate in normal neuronal
physiology [4, 24, 26]. A study of human brain injury
by Majetschak et al, showed a progressive rise of CSF
ubiquitin levels in traumatic brain injury patients who
succumbed to their injuries compared with those who
survived [16].
Our observations are the first to show an increase in circu-
lating proteasome activity in the plasma in children hospital-
ized because ofmild head injury. Our results also demonstrate,
that molecular changes affecting protein metabolism, occur
soon after head injury, and there is a downward trend in the c-
proteasome activity in the plasma of children with mild head
injury along with the resolving of the symptoms of the cere-
bral concussion.
Conclusions
Authors observed a statistically significant upward trend
in the c-proteasome activity between 2–6 and 12-16
after the mild head injury, consistent with the onset of
the symptoms of cerebral concussion, and a downward
trend in the c-proteasome activity in the plasma of
children with mild head injury between 12–16 h and
on the second day after the injury, consistent with the
resolving of the symptoms of cerebral concussion. Fur-
ther studies are needed to demonstrate that the protea-
some activity could be a prognostic factor, which can
help in further diagnostic and therapeutic decisions in
patients with head injury.
























Fig. 1 Circulating proteasome
activity in the plasma of children,
2–6 h (1, n=50), 12–16 h
(2, n=45), 2 days (3, n=41)
after mild head injury and in
control group
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